PetVivo (PETV) Q1 2027 earnings summary

Executive summary

• Achieved 13% year-over-year revenue growth to $338,000, driven by proprietary SPRYNG product focus, expanded sales force, and distributor partnerships, with Spryng as the lead product for osteoarthritis in dogs and horses.

• Entered agreement to acquire PiezoBioMembrane (PBM), enhancing R&D and IP portfolio for regenerative biomaterials targeting animal and human health, with acquisition expected to be transformative pending financing.

• Advanced commercialization of AI-powered PetVivo.ai platform, targeting veterinary practice efficiency, customer acquisition, and high-margin recurring revenue.

• Secured Health Canada recognition for SPRYNG, enabling commercialization in Canada and expanding international reach.

• Strengthened partnerships with Digital Landia and Veterinary Growth Partners to drive product adoption and market expansion, and entered exclusive licensing for AgenticPet AI technology.

Financial highlights

• Revenue for the quarter was $337,572, up 13% year-over-year and 33% sequentially, with gross profit rising to $223,317 (66% margin).

• Operating expenses decreased to $1,832,166, with R&D down 31% and G&A down 9%, offset by a 2% increase in sales and marketing.

• Operating loss improved to $1,608,849, and net loss narrowed to $1,613,888 ($0.05/share), a 30% improvement year-over-year.

• Net cash used in operations dropped 40% to $965,779; quarter-end cash was $122,633, with $1.35 million in equity subscription pending.

• Weighted average shares outstanding increased to 37,055,261 from 24,302,790 year-over-year.

Outlook and guidance

• Anticipates continued sales momentum and market penetration for fiscal 2027 and beyond, supported by new product launches and international expansion.

• Expects gross margins to return to 80-90% as sales transition fully to proprietary products.

• Plans to announce commercial launch of PetVivo.ai within months and secure Canadian distributors soon, targeting SaaS recurring revenue.

• Ongoing efforts to secure government grants, R&D tax credits, and FDA clearance for human applications of PBM-enhanced products.

• Management is negotiating for up to $10 million in new investment and expects to continue raising capital to fund operations and expansion.